Tickers

1. Composite Trajectory Verdict

For a mature consumer staples company like PG, all three financial statements carry roughly equal weight: the income statement shows pricing power and margin trajectory, the cash flow statement reflects the ability to fund dividends, buybacks, and reinvestment, and the balance sheet indicates financial flexibility and resilience.

Composite Trajectory: Mixed

The annual income statement shows deteriorating profitability: operating income fell 3% to $19.7B despite 3% revenue growth, with operating margin contracting 160 bps to 22.7% (10-K 2026-06-30, Consolidated Statements of Earnings; MD&A). The cash flow statement shows clear improvement: operating cash flow rose 10% to $19.6B and adjusted free cash flow productivity reached 100% vs 87% a year earlier (10-K 2026-06-30, Consolidated Statements of Cash Flows; MD&A). The balance sheet is stable: total assets grew 1% to $126.5B, total liabilities declined 1% to $72.2B, and equity rose 4% to $54.3B, though current liabilities exceed current assets by $12.5B (10-K 2026-06-30, Consolidated Balance Sheets; Liquidity). Quarterly trends show revenue accelerating (+7% in Q3 FY2026) but operating income flat, reinforcing the mixed picture (10-Q 2026-03-31, Results of Operations).

2. Red Flags

• Operating income declined 3% ($19.7B vs $20.5B) while net sales rose 3% ($87.0B vs $84.3B), driving a 160 bps operating margin contraction to 22.7% (10-K 2026-06-30, Consolidated Statements of Earnings; MD&A Operating Costs).
• Gross margin fell 100 bps to 50.2% due to unfavorable mix (-120 bps), product/packaging investment (-70 bps), restructuring (-60 bps), tariff costs (-30 bps), and commodity costs (-20 bps), only partially offset by productivity (+180 bps) and pricing (+40 bps) (10-K 2026-06-30, MD&A Operating Costs).
• SG&A as a percentage of sales increased 60 bps to 27.5%, driven by an 80 bps rise in marketing spend as a percentage of sales (10-K 2026-06-30, MD&A Operating Costs).
• Current liabilities ($38.7B) exceed current assets ($26.2B) by $12.5B, a persistent working capital deficit (10-K 2026-06-30, Liquidity).
• Restructuring charges have been sizable for three consecutive years: $1.2B in FY2026, $1.1B in FY2025, $0.7B in FY2024 (before tax), labeled "incremental" or "non-core" but recurring (10-K 2026-06-30, Note 3).
• The Gillette indefinite-lived intangible asset carries a $12.8B carrying value with fair value exceeding carrying value by only >10%, and management notes it is "susceptible to impairment risk" from currency devaluation, inflation, or market contraction (10-K 2026-06-30, Critical Accounting Policies).
• Core EPS ($6.89) exceeds GAAP diluted EPS ($6.62) by $0.27, with the gap driven by $904M incremental restructuring and a $261M Glad JV gain (10-K 2026-06-30, Reconciliation of Non-GAAP Measures).
• Inventories consumed $641M of cash in FY2026 (days inventory on hand +2 days), while accounts payable generated $919M (10-K 2026-06-30, Operating Cash Flow).
• Debt due within one year rose to $11.3B from $9.5B, increasing near-term refinancing needs (10-K 2026-06-30, Consolidated Balance Sheets; Note 10).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual results show top-line growth but margin compression: net sales rose 3% to $87.0B (organic +1%), yet operating income fell 3% to $19.7B and net earnings were essentially flat at $16.1B (+0.5%) (10-K 2026-06-30, Consolidated Statements of Earnings). Diluted EPS grew 2% to $6.62, aided by share count reduction. Gross margin contracted 100 bps to 50.2%, operating margin 160 bps to 22.7%, and net margin 60 bps to 18.5% (10-K 2026-06-30, MD&A Operating Costs). Quarterly trends are more favorable on the top line: Q3 FY2026 net sales rose 7% to $21.2B with organic growth of 3%, but operating income was flat at $4.6B; nine-month operating income declined 2% to $15.8B on 4% sales growth (10-Q 2026-03-31, Results of Operations). Segment performance diverges: Beauty organic sales +5% (FY) but net earnings -2%; Fabric & Home Care organic +1% but net earnings -4%; Baby, Feminine & Family Care organic -1% (10-K 2026-06-30, Segment Results).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Operating cash flow rebounded strongly in FY2026 to $19.6B (+10% vs $17.8B in FY2025), recovering from a dip in FY2025 ($19.8B in FY2024) (10-K 2026-06-30, Consolidated Statements of Cash Flows). Capital expenditures rose 17% to $4.4B, yielding GAAP free cash flow (OCF - CapEx) of $15.1B (+7.8%). Adjusted free cash flow (excluding transitional tax payments) increased 8% to $15.8B, and adjusted free cash flow productivity reached 100% vs 87% in FY2025 (10-K 2026-06-30, Cash Flow Analysis; Reconciliation of Non-GAAP Measures). Nine-month FY2026 operating cash flow was $14.4B with adjusted free cash flow of $11.7B (10-Q 2026-03-31, Summary of Results). Dividends paid rose 3.6% to $10.2B and share repurchases fell 23% to $5.0B (10-K 2026-06-30, Consolidated Statements of Cash Flows). The cash conversion profile has improved materially year-over-year.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Stable

Total assets grew 1% to $126.5B, total liabilities declined 1% to $72.2B, and shareholders' equity rose 4% to $54.3B (10-K 2026-06-30, Consolidated Balance Sheets). Total debt (current + long-term) was roughly flat at $34.5B ($11.3B current + $22.8B long-term vs $9.5B + $25.0B) (10-K 2026-06-30, Consolidated Balance Sheets; Note 10). Cash and equivalents increased 4% to $9.9B. Goodwill declined 1% to $41.3B and intangible assets 2% to $21.4B, primarily due to currency translation (10-K 2026-06-30, Note 4). Treasury stock grew to $143.0B from $138.7B, reflecting ongoing buybacks. Retained earnings rose 4.5% to $135.9B. The persistent current liability excess ($12.5B) and elevated near-term debt maturities ($11.3B due within one year) are structural features, not new deteriorations (10-K 2026-06-30, Liquidity; Contractual Commitments).

6. Data Gaps

• Quarterly cash flow statements for Q3 FY2025, Q2 FY2026, and Q1 FY2026 (only nine-month FY2026 OCF and adjusted FCF disclosed in 10-Q 2026-03-31; prior-year quarterly cash flows not in provided filings).
• Full quarterly income statement detail (gross margin, SG&A components) for Q2 FY2026 and Q1 FY2026 (only net sales, operating income, net earnings, EPS summarized in 10-Q MD&A tables).
• Organic sales growth by segment for quarterly periods (only annual organic growth by segment in 10-K; quarterly MD&A gives net sales drivers but not explicit organic % by segment).
• Working capital metrics (DSO, DIO, DPO) for quarterly periods (only annual changes disclosed in 10-K Operating Cash Flow section).
• Nine-month FY2025 operating cash flow and adjusted free cash flow (referenced as "prior year period" in 10-Q 2026-03-31 but not quantified in provided excerpt).